- Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East, Middle East and Africa (NEMEA) countries. Acino to get rights, title, and interest to the products in the portfolio exclusive in NEMEA. The transaction is expected to close in Q4’19
- Additionally, Takeda and Acino will sign multi-year manufacturing and supply agreement under which Takeda will continue to manufacture the products on behalf of Acino
- The collaboration will optimize Takeda’s portfolio in the NEMEA region, reduces its debt and accelerates deleveraging towards reaching its target of 2.0x net debt/adjusted EBITDA in the next 3-5yrs.
Click here to read full press release/ article | Ref: Takeda| Image: Fortune